Burkhard Jansen

TL;DR: It is shown that in cells transiently transfected with bax, Bax localizes to mitochondria and induces the release of cytochrome c, activation of caspase-3, membrane blebbing, nuclear fragmentation, and cell death, indicating that Bcl-2 can interfere with Bax killing downstream of and independently of cy tochrome c release.

TL;DR: It is demonstrated that bcl-2 antisense oligonucleotide treatment improves the chemo-sensitivity of human melanoma grown in severe combined im-munodeficient (SCID) mice and suggests that reduction of B cl-2 in melanoma may be a novel and rational approach to improve chemosensitivity and treatment outcome.

TL;DR: Systemic administration of augmerosen downregulated the target BCL2 protein in metastatic cancer, combined with standard anticancer therapy, offers a new approach to the treatment of patients with resistant neoplasms.

TL;DR: It is demonstrated that CLU knockdown in human cancer cells induces significant reduction of cellular growth and higher rates of spontaneous endogenous apoptosis, and siRNA-mediated CLU gene silencing in osteosarcoma and prostate cancer cells proves valuable agents during antitumor therapy or at other pathological conditions where CLU has been implicated.

TL;DR: In this article, the authors employed immortalized murine hepatocytes, which display a high degree of differentiation and, expectedly, arrest in the G1 phase under exposure to TGF-β1.